Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models

Convincing evidence supports the premise that reducing α-synuclein levels may be an effective therapy for Parkinson’s disease (PD); however, there has been lack of a clinically applicable α-synuclein reducing therapeutic strategy. This study was undertaken to develop a blood-brain barrier and plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Jack Wuyang, Fan, Xuelai, del Cid-Pellitero, Esther, Liu, Xing-Xing, Zhou, Limin, Dai, Chunfang, Gibbs, Ebrima, He, Wenting, Li, Hongjie, Wu, Xiaobin, Hill, Austin, Leavitt, Blair R., Cashman, Neil, Liu, Lidong, Lu, Jie, Durcan, Thomas M., Dong, Zhifang, Fon, Edward A., Wang, Yu Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895943/
https://www.ncbi.nlm.nih.gov/pubmed/33608634
http://dx.doi.org/10.1038/s42003-021-01746-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895943/
https://www.ncbi.nlm.nih.gov/pubmed/33608634
http://dx.doi.org/10.1038/s42003-021-01746-6

Ejemplares similares